{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T20:11:21Z","timestamp":1780344681511,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.farma.2026.05.001","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:44:43Z","timestamp":1780343083000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Translated article] Possible severe gastrointestinal toxicity following the first cycle of mirvetuximab soravtansine in a patient with high-grade serous ovarian carcinoma"],"prefix":"10.1016","author":[{"given":"Carlota","family":"Rodr\u00edguez-Tenreiro Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Caso Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mu\u00f1oz Villasur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Roncero S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Lozano Bl\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2026.05.001_bb0005","author":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM). El c\u00e1ncer en cifras. SEOM"},{"issue":"10","key":"10.1016\/j.farma.2026.05.001_bb0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.farma.2026.05.001_bb0015","author":"European Medicines Agency. Ficha t\u00e9cnica de Mirvetuximab soravtansina (Elahere\u00ae). European Medicines Agency"},{"key":"10.1016\/j.farma.2026.05.001_bb0020","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.30736","article-title":"Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor \u03b1-targeting antibody-drug conjugate, in patients with solid tumors","volume":"123","author":"Moore","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.farma.2026.05.001_bb0025","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.farma.2026.05.001_bb0030","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Gynecologic oncology group partners and the European network of gynaecological oncological trial groups. Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.farma.2026.05.001_bb0035","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.farma.2026.05.001_bb0040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2024.10.013","article-title":"Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: an integrated safety summary","volume":"191","author":"Moore","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.farma.2026.05.001_bb0045","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","article-title":"The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial","volume":"36","author":"Alvarez Secord","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.farma.2026.05.001_bb0050","author":"European Medicines Agency. EudraVigilance \u2013 European database of suspected adverse drug reaction reports. Amsterdam: EMA"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:44:44Z","timestamp":1780343084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326001121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":10,"alternative-id":["S1130634326001121"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.05.001","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Possible severe gastrointestinal toxicity following the first cycle of mirvetuximab soravtansine in a patient with high-grade serous ovarian carcinoma","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.03.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}